Kyverna Therapeutics, Inc. (KYTX) intrinsic value & 10-year financials
Kyverna Therapeutics, Inc. (KYTX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $5.67
- Market cap
- $251.0M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -684.8%
- Free cash flow (FY2025)
- -$153.7M
KYTX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$161.3M | -$3.64 | -$153.7M | — | -110.5% |
| FY2024 | — | -$127.5M | -$3.33 | -$116.5M | — | -1983.0% |
| FY2023 | — | -$60.4M | -$1.57 | -$53.0M | — | 39.0% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Kyverna Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Kyverna Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -30.4% ROIC.
Kyverna Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Kyverna Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.